Only tucatinib [18], lapatinib, and neratinib ended up investigated in possible scientific tests and showed good response rates and reaction duration. During the HER2CLIMB demo the secondary endpoint of PFS in individuals with Mind metastases showed a major reduction in the risk of development or Dying by 52% inside the tucatinib arm. While in th